Mylan Pharmaceuticals has lost its bid to deem an Australian producer of acne medication in violation of antitrust laws for alleged “product-hopping.”
U.S. District Judge Paul S. Diamond of the Eastern District of Pennsylvania ruled last week in Mylan Pharmaceuticals v. Warner Chilcott Public Ltd. that efforts by Australian company Mayne Pharmaceuticals to make various changes to its acne drug Doryx over several years was not anti-competitive even if it kept generic versions off the market for a longer time period.